Effect of γ-cyclodextrin on solubilization and complexation of irbesartan: Influence of pH and excipients

International Journal of Pharmaceutics

Volumn 474, Issue 1-2, 2014, Pages 80-90

  Muankaew, Chutimon ^a,b   Jansook, Phatsawee ^c   Stefánsson, Einar ^d   Loftsson, Thorsteinn ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

^b SIAM UNIVERSITY   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Complexation; Excipient; Irbesartan; pH; Solubilization; Cyclodextrin

Indexed keywords

BENZALKONIUM CHLORIDE; EDETATE DISODIUM; EDETIC ACID; GAMMA CYCLODEXTRIN; HYDROXYPROPYLMETHYLCELLULOSE; IRBESARTAN; TYLOXAPOL; EXCIPIENT; EYE DROPS; BIPHENYL DERIVATIVE; GAMMA CYCLODEXTRIN DERIVATIVE; GAMMA-CYCLODEXTRIN; TETRAZOLE DERIVATIVE;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG SOLUBILITY; EXCIPIENT COMPATIBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; LIGHT SCATTERING; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION; PH; CHEMICAL STRUCTURE; CHEMISTRY; SOLUBILITY;

BIPHENYL COMPOUNDS; EXCIPIENTS; GAMMA-CYCLODEXTRINS; HYDROGEN-ION CONCENTRATION; MOLECULAR STRUCTURE; SOLUBILITY; TETRAZOLES;

EID: 84906512158     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.08.013     Document Type: Article

References (70)

1. A.A. Abd El-Bary, H.F. Salem, and R.M. Kharshoum 2-Hydroxypropyl-β- cyclodextrin complex with ketotifen fumarate for eye drops preparations Int. J. Drug Deliv. 3 2011 228 240
2. F. Acarturk, and N. Celebi Cyclodextrins as Bioavailability Enhancers 2011 John Wiley & Sons, Inc. 45 64
3. M.S. Aruna, A.K. Babu, M. Thadanki, and M.E. Gupta Solid dispersions - an approach to enhance the dissolution rate of irbesartan Int. J. Res. Pharm. Chem. 1 2011 780 788
4. O.-M. Ba, M. Lahiani-Skiba, S. Joudieh, F. Bounoure, and M. Skiba Influence of Water-Soluble Polymers, pH and Surfactants on Mebendazole (MBZ) Solubilization by β-and Partially Methylated-β-cyclodextrins 2008 CRC Press 386 389
5. M. Bonini, S. Rossi, G. Karlsson, M. Almgren, N.P. Lo, and P. Baglioni Self-assembly of β-cyclodextrin in water. Part 1: cryo-TEM and dynamic and static light scattering Langmuir 22 2006 1478 1484
6. M.E. Brewster, and T. Loftsson Cyclodextrins as pharmaceutical solubilizers Adv. Drug Deliv. Rev. 59 2007 645 666 (Pubitemid 47299263)
7. J. Bügler, N.A.J.M. Sommerdijk, A.J.W.G. Visser, A. van Hoek, R.J.M. Nolte, J.F.J. Engbersen, and D.N. Reinhoudt Interconnective host-guest complexation of β-cyclodextrin-calix 4 arene couples J. Am. Chem. Soc. 121 1998 28 33 (Pubitemid 29047118)
8. R.L. Carrier, L.A. Miller, and I. Ahmed The utility of cyclodextrins for enhancing oral bioavailability J. Control. Release 123 2007 78 99 (Pubitemid 47566400)
9. G. Chawla, and A.K. Bansal A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug Eur. J. Pharm. Sci 32 2007 45 57 (Pubitemid 47411498)
10. A. Clermont, S.-E. Bursell, and E.P. Feener Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond J. Hypertens. 24 2006 S73 S80
11. E.C. Demiralay, B. Cubuk, S.A. Ozkan, and G. Alsancak Combined effect of polarity and pH on the chromatographic behavior of some angiotensin II receptor antagonists and optimization of their determination in pharmaceutical dosage forms J. Pharm. Biomed. Anal. 53 2010 475 482
12. M.T. Faucci, and P. Mura Effect of water-soluble polymers on naproxen complexation with natural and chemically modified β-cyclodextrins Drug Dev. Ind. Pharm. 27 2001 909 917 (Pubitemid 33101450)
13. T. Fujita, K. Hirooka, T. Nakamura, T. Itano, A. Nishiyama, Y. Nagai, and F. Shiraga Neuroprotective effects of angiotensin II type 1 receptor (AT1-R) blocker via modulating AT1-R signaling and decreased extracellular glutamate levels Invest. Ophthalmol. Vis. Sci. 53 2012 4099 4110
14. A. Gillet, A. Grammenos, P. Compere, B. Evrard, and G. Piel Development of a new topical system drug-in-cyclodextrin-in-deformable liposome Int. J. Pharm. 380 2009 174 180
15. A. Gillet, F. Lecomte, P. Hubert, E. Ducat, B. Evrard, and G. Piel Skin penetration behaviour of liposomes as a function of their composition Eur. J. Pharm. Biopharm. 79 2011 43 53
16. G. Gonzalez-Gaitano, P. Rodriguez, J.R. Isasi, M. Fuentes, G. Tardajos, and M. Sanchez The aggregation of cyclodextrins as studied by photon correlation spectroscopy J. Incl. Phenom. Macrocycl. Chem. 44 2003 101 105
17. G.E. Granero, and M.R. Longhi Promising complexes of acetazolamide for topical ocular administration Expert Opin. Drug Deliv. 7 2010 943 953
18. B.S. Gudmundsdottir, D. Petursdottir, G.M. Asgrimsdottir, M.S. Gottfredsdottir, S.H. Hardarson, G. Johannesson, S.V. Kurkov, P. Jansook, T. Loftsson, and E. Stefansson γ-Cyclodextrin nanoparticle eye drops with dorzolamide: effect on intraocular pressure in man J. Ocul. Pharmacol. Ther. 30 2014 35 41
19. T. Higuchi, and K.A. Connors Phase-solubility techniques Advan. Anal. Chem. Instr. 4 1965 117 212
20. R. Hirlekar, and V. Kadam Preformulation study of the inclusion complex irbesartan-β-cyclodextrin AAPS PharmSciTech 10 2009 276 281
21. R.S. Hirlekar, S.N. Sonawane, and V.J. Kadam Studies on the effect of water-soluble polymers on drug-cyclodextrin complex solubility AAPS PharmSciTech 10 2009 858 863
22. S.A. Jain, and N.S. Kurup Formulation of irbesartan by microcrystal technology for enhancing the solubility and dissolution properties Int. J. Pharm. Sci. Nanotechnol. 6 2013 2064 2076
23. P. Jansook, and T. Loftsson CDs as solubilizers effects of excipients and competing drugs Int. J. Pharm. 379 2009 32 40
24. P. Jansook, M.D. Moya-Ortega, and T. Loftsson Effect of self-aggregation of γ-cyclodextrin on drug solubilization J. Incl. Phenom. Macrocycl. Chem. 68 2010 229 236
25. P. Jansook, E. Stefansson, M. Thorsteinsdottir, B.B. Sigurdsson, S.S. Kristjansdottir, J.F. Bas, H.H. Sigurdsson, and T. Loftsson Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension Eur. J. Pharm. Biopharm. 76 2010 208 214
26. P. Jansook, C. Muankaew, E. Stefansson, and T. Loftsson Development of eye drops containing antihypertensive drugs: formulation of aqueous irbesartan/γCD eye drops Pharm. Dev. Technol. 2014
27. G. Johannesson, M.D. Moya-Ortega, G.M. Asgrimsdottir, B.A. Agnarsson, S.H. Lund, T. Loftsson, and E. Stefansson Dorzolamide cyclodextrin nanoparticle suspension eye drops and trusopt in rabbit J. Ocul. Pharmacol. Ther. 2014
28. G. Johannesson, M.D. Moya-Ortega, G.M. Asgrimsdottir, S.H. Lund, M. Thorsteinsdottir, T. Loftsson, and E. Stefansson Kinetics of γ-cyclodextrin nanoparticle suspension eye drops in tear fluid Acta Ophthalmol. 2013
29. I.P. Kaur, M. Singh, and M. Kanwar Formulation and evaluation of ophthalmic preparations of acetazolamide Int. J. Pharm 199 2000 119 127 (Pubitemid 30236183)
30. K. Kavitha, P. Santhosh Kumar, M. Rupeshkumar, and G. Piyush Developments and advanced approaches of ophthalmic drug delivery system: a review Int. J. Curr. Pharm. Res. 5 2013 4 9
31. F. Konradsdottir, H. Ogmundsdottir, V. Sigurdsson, and T. Loftsson Drug targeting to the hair follicles: a cyclodextrin-based drug delivery AAPS PharmSciTech 10 2009 266 269
32. S.V. Kurkov, and T. Loftsson Cyclodextrins Int. J. Pharm. (Amsterdam, Neth.) 453 2013 167 180
33. J. Lehmann, E. Kleinpeter, and J. Krechl Proton NMR spectroscopy as a probe of intermolecular interactions in β-cyclodextrin inclusion compounds J. Incl. Phenom. Mol. Recognit. Chem. 10 1991 233 239
34. T. Loftsson Self-assembled cyclodextrin nanoparticles and drug delivery J. Incl. Phenom. Macrocycl. Chem. 2013
35. T. Loftsson, and D. Duchene Cyclodextrins and their pharmaceutical applications Int. J. Pharm. 329 2007 1 11 (Pubitemid 44937538)
36. T. Loftsson, and H. Frioriksdottir The effect of water-soluble polymers on the aqueous solubility and complexing abilities of β-cyclodextrin Int. J. Pharm. 163 1998 115 121 (Pubitemid 28162625)
37. T. Loftsson, D. Hreinsdottir, and M. Masson Evaluation of cyclodextrin solubilization of drugs Int. J. Pharm. 302 2005 18 28 (Pubitemid 41244817)
38. T. Loftsson, D. Hreinsdottir, and M. Masson The complexation efficiency J. Incl. Phenom. Macrocycl. Chem. 57 2007 545 552
39. T. Loftsson, D. Hreinsdottir, and E. Stefansson Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops J. Pharm. Pharmacol. 59 2007 629 635 (Pubitemid 47051105)
40. T. Loftsson, and M. Masson The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs J. Drug Deliv. Sci. Technol. 14 2004 35 43 (Pubitemid 38436213)
41. T. Loftsson, M. Masson, and H.H. Sigurdsson Cyclodextrins and drug permeability through semi-permeable cellophane membranes Int. J. Pharm. 232 2002 35 43 (Pubitemid 34076752)
42. T. Loftsson, K. Matthiasson, and M. Masson The effects of organic salts on the cyclodextrin solubilization of drugs Int. J. Pharm. 262 2003 101 107 (Pubitemid 36966698)
43. G.O.K. Loh, Y.T.F. Tan, and K.K. Peh Effect of HPMC concentration on β-cyclodextrin solubilization of norfloxacin Carbohydr. Polym. 101 2014 505 510
44. N.N. Madhuri Divya, M. Muthukumaran, and B. Krishnamoorthy A review on recent studies and advances in ocular drug delivery system Res. J. Pharm. Biol. Chem. Sci. 4 2013 529 545
45. A.K. Meka, S. Pola, K.R. Tupally, and P.L. Abbaraju Development evaluation and characterization of surface solid dispersion for solubility and dissolution enhancement of irbesartan Int. J. Drug Dev. Res. 4 2012 263 273
46. M. Messner, S.V. Kurkov, M.E. Brewster, P. Jansook, and T. Loftsson Self-assembly of cyclodextrin complexes: aggregation of hydrocortisone/ cyclodextrin complexes Int. J. Pharm. 407 2011 174 183
47. M. Messner, S.V. Kurkov, R. Flavia-Piera, M.E. Brewster, and T. Loftsson Self-assembly of cyclodextrins: the effect of the guest molecule Int. J. Pharm. 408 2011 235 247
48. M. Messner, S.V. Kurkov, M.M. Palazon, B.A. Fernandez, M.E. Brewster, and T. Loftsson Self-assembly of cyclodextrin complexes: effect of temperature agitation and media composition on aggregation Int. J. Pharm. 419 2011 322 328
49. V. Monnaert, S. Tilloy, H. Bricout, L. Fenart, R. Cecchelli, and E. Monflier Behavior of α-, β-, and γ-cyclodextrins and their derivatives on an in vitro model of blood-brain barrier J. Pharmacol. Exp. Ther. 310 2004 745 751 (Pubitemid 38988921)
50. I.C. Munro, P.M. Newberne, V.R. Young, and A. Bar Safety assessment of γ-cyclodextrin Regul. Toxicol. Pharmacol. 39 2004 S3 S13
51. I. Muszalska, A. Sobczak, A. Dolhan, and A. Jelinska Analysis of sartans: a review J. Pharm. Sci. 103 2014 2 28
52. J.S. Negi, and S. Singh Spectroscopic investigation on the inclusion complex formation between amisulpride and γ-cyclodextrin Carbohydr. Polym. 92 2013 1835 1843
53. J. Patel, A. Patel, M. Raval, and N. Sheth Formulation and development of a self-nanoemulsifying drug delivery system of irbesartan J. Adv. Pharm. Technol. Res. 2 2011 9 16
54. A. Pineiro, X. Banquy, S. Perez-Casas, E. Tovar, A. Garcia, A. Villa, A. Amigo, A.E. Mark, and M. Costas On the characterization of host-guest complexes: surface tension, calorimetry, and molecular dynamics of cyclodextrins with a non-ionic surfactant J. Phys. Chem. B 111 2007 4383 4392 (Pubitemid 46787632)
55. N. Rajendiran, and S. Siva Inclusion complex of sulfadimethoxine with cyclodextrins preparation and characterization Carbohydr. Polym. 101 2014 828 836
56. O. Regev, and R. Zana Aggregation behavior of tyloxapol, a nonionic surfactant oligomer, in aqueous solution J. Colloid Interface Sci. 210 1999 8 17 (Pubitemid 29394475)
57. L.S.S. Ribeiro, D.C. Ferreira, and F.J.B. Veiga Physicochemical investigation of the effects of water-soluble polymers on vinpocetine complexation with β-cyclodextrin and its sulfobutyl ether derivative in solution and solid state Eur. J. Pharm. Sci. 20 2003 253 266 (Pubitemid 37338531)
58. R.M.E. Richards, and R.J. McBride Enhancement of benzalkonium chloride and chlorhexidine acetate activity against Pseudomonas aeruginosa by aromatic alcohols J. Pharm. Sci. 62 1973 2035 2037
59. G. Ryan Jr., J.M. Fain, C. Lovelace, and K.M. Gelotte Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system BMC Ophthalmol. 11 2011 8
60. Z. Sklubalova Antimicrobial substances in ophthalmic drops Ceska Slov. Farm. 53 2004 107 116 (Pubitemid 38619574)
61. M. Tanito, K. Hara, Y. Takai, Y. Matsuoka, N. Nishimura, P. Jansook, T. Loftsson, E. Stefansson, and A. Ohira Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema Invest. Ophthalmol. Vis. Sci. 52 2011 7944 7948
62. T. Taupitz, J.B. Dressman, C.M. Buchanan, and S. Klein Cyclodextrin-water soluble polymer ternary complexes enhance the solubility and dissolution behaviour of poorly soluble drugs. Case example: itraconazole Eur. J. Pharm. Biopharm. 83 2013 378 387
63. R.S. Teixeira, F.J.B. Veiga, R.S. Oliveira, S.A. Jones, S.M.C. Silva, R.A. Carvalho, and A.J.M. Valente Effect of cyclodextrins and pH on the permeation of tetracaine: supramolecular assemblies and release behavior Int. J. Pharm. 466 2014 349 358
64. A.J.M. Valente, and O. Soderman The formation of host-guest complexes between surfactants and cyclodextrins Adv. Colloid Interface Sci. 205 2014 156 176
65. M.D. Veiga, and F. Ahsan Influence of surfactants (present in the dissolution media) on the release behavior of tolbutamide from its inclusion complex with β-cyclodextrin Eur. J. Pharm. Sci. 9 2000 291 299
66. Z. Vujic, N. Mulavdic, M. Smajic, J. Brboric, and P. Stankovic Simultaneous analysis of irbesartan and hydrochlorothiazide: an improved HPLC method with the aid of a chemometric protocol Molecules 17 2012 3461 3474
67. A. Wu, X. Shen, and Y. He Investigation on γ-cyclodextrin nanotube induced by N,N′-diphenylbenzidine molecule J. Colloid Interface Sci. 297 2006 525 533
68. M. Yoshida, T. Ueda, T. Noda, S. Shimada, R. Koide, S.-y. Go, T. Hisamitsu, and K. Oguchi The mechanism of ocular hypotensive effect of CS-088, angiotensin II type I receptor blocker, in pigmented rabbit Investigation of central ocular hypotensive effect Showa Igakkai Zasshi 64 2004 199 205 (Pubitemid 39108395)
69. K. Zhang, L. Zhang, and R.N. Weinreb Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma Nat. Rev. Drug Discov. 11 2012 541 559
70. Z.-L. Zhang, Y. Le, J.-X. Wang, and J.-F. Chen Preparation of stable micron-sized crystalline irbesartan particles for the enhancement of dissolution rate Drug Dev. Ind. Pharm. 37 2011 1357 1364